GILD · Gilead Sciences Inc
United States · RS rating 93 · As of 2026-10-14
| Price | 153.54 USD |
|---|---|
| 1-day change | +3.8% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 89 / 87 / 83 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 46 / 52 / 48 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -28.4% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +1.4% |
| Market cap (USD) | $165.9B |